Skip to Content

Predicting Liver Toxicity

A new way to keep human liver cells alive in the lab could help researchers weed out toxic drugs before they get to market.
February 16, 2006

Every year unforeseen toxicity scuttles new drugs, sometimes even after they’ve received FDA approval. A major reason is that it’s difficult to predict the response of the liver, where drug toxicity often shows up.

“Liver toxicity issues are the primary reason for drug recall and withdrawal,” according to Yvonne Dragan, director of systems toxicology at the FDA’s National Center for Toxicological Research.

So it’s not surprising that mimicking liver toxicity in the lab would be the centerpiece of efforts to predict a drug’s toxicity early in the development process.

In the past, such screenings have been difficult because actual liver cells, once they are taken from the body, stop acting like liver cells within a day. But now Sangeeta Bhatia, an M.D., medical engineer, and associate professor at MIT, has found a way to keep liver cells doing their job for weeks. What’s more, she has developed a method for arranging them in multiple test wells, allowing drug researchers to screen multiple compounds at the same time.

Because the liver cells function for such a long time, they can be used to test for chronic toxicity, which is caused by low-level exposure to a compound over time. “That’s something you can’t do in other platforms currently in use,” says Bhatia.

Bhatia’s innovation was to develop a way of organizing the liver cells using photolithography, the same process used to create computer microprocessors. First, a pattern is created in test wells for a layer of proteins. Then liver cells are applied, which stick to the proteins, replicating the patterns. Finally, supportive cells are added, filling in around the liver cells.

Using this technique, Bhatia was able to experiment with many different configurations of the two cell types, until she found the one that kept the liver cells functioning for weeks.

That is, she found the pattern that works for rat liver cells. As it turns out, “human cells are completely different,” says Bhatia. Applying a technique called “soft lithography,” which uses a polymer stencil to pattern the proteins, Bhatia found patterns that let human liver cells function for a month. Then she tested to see if these liver cells could correctly predict the effect that drugs would have on a human liver.

It worked: the more toxic a drug was known to be, the more toxic its effect was on her mini-livers. Indeed, one of the drugs that showed up as highly toxic in her tests had already been pulled from the market after causing problems in humans.

Bhatia is not the only researcher working on using liver cells to better predict toxicity. Companies such as Hurel of Beverly Hills, CA, and RegeneMed of La Jolla, CA, have developed toxicology screenings that also use liver cells.

One of Bhatia’s colleagues at MIT, Linda Griffith, along with research scientist Karel Domansky, has built a system that encloses three-dimensional liver tissue and perfuses it with nutrients using microfluidics. Griffith’s cells also retain their functions over time, and so could also be used to test for chronic toxicity. Her lab is working with DuPont on evaluating the system for commercialization

Although Bhatia’s current liver model is promising, it’s not a panacea, according to the FDA’s Dragan. “It’s a wonderful model,” she says, especially because it can screen for chronic toxicity. But Dragan cautions that “it’s still derived from a single human liver.” This means Bhatia’s model might fail to predict how people with genetic differences or unusual medical histories would react to a drug.

Bhatia says that future screenings could incorporate different livers. For now, says Dragan, “It will not substitute for human trials. But it will be useful for screening out bad actors.”

Keep Reading

Most Popular

It’s time to retire the term “user”

The proliferation of AI means we need a new word.

Sam Altman says helpful agents are poised to become AI’s killer function

Open AI’s CEO says we won’t need new hardware or lots more training data to get there.

An AI startup made a hyperrealistic deepfake of me that’s so good it’s scary

Synthesia's new technology is impressive but raises big questions about a world where we increasingly can’t tell what’s real.

Taking AI to the next level in manufacturing

Reducing data, talent, and organizational barriers to achieve scale.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.